- Home
- NAUT vs CLLS Comparison
NAUT vs CLLS Comparison
Compare NAUT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- CLLS
- Stock Information
- Founded
- NAUT 2016
- CLLS 1999
- Country
- NAUT United States
- CLLS France
- Employees
- NAUT N/A
- CLLS N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- CLLS Health Care
- Exchange
- NAUT Nasdaq
- CLLS Nasdaq
- Market Cap
- NAUT 284.7M
- CLLS 240.2M
- IPO Year
- NAUT N/A
- CLLS 2007
- Fundamental
- Price
- NAUT $2.38
- CLLS $1.86
- Analyst Decision
- NAUT Buy
- CLLS Buy
- Analyst Count
- NAUT 2
- CLLS 3
- Target Price
- NAUT $4.50
- CLLS $7.00
- AVG Volume (30 Days)
- NAUT 116.7K
- CLLS 90.3K
- Earning Date
- NAUT 10-29-2024
- CLLS 11-04-2024
- Dividend Yield
- NAUT N/A
- CLLS N/A
- EPS Growth
- NAUT N/A
- CLLS N/A
- EPS
- NAUT N/A
- CLLS N/A
- Revenue
- NAUT N/A
- CLLS $36,042,000.00
- Revenue This Year
- NAUT N/A
- CLLS $271.02
- Revenue Next Year
- NAUT N/A
- CLLS $33.48
- P/E Ratio
- NAUT N/A
- CLLS N/A
- Revenue Growth
- NAUT N/A
- CLLS 46.96
- 52 Week Low
- NAUT $2.19
- CLLS $1.70
- 52 Week High
- NAUT $3.46
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- NAUT 42.12
- CLLS 46.46
- Support Level
- NAUT $2.21
- CLLS $1.77
- Resistance Level
- NAUT $2.92
- CLLS $1.98
- Average True Range (ATR)
- NAUT 0.17
- CLLS 0.10
- MACD
- NAUT -0.02
- CLLS 0.02
- Stochastic Oscillator
- NAUT 24.01
- CLLS 53.37
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.